The current standard treatment for Fabry disease is enzyme replacement therapy (ERT) by intravenous administration of an enzyme replacement with either of two enzymes, agalsidase-alfa (Shire HGT) or agalsidase-beta (Genzyme Corp). The gene discussed is GLA; the disease is Fabry disease.